1	Bacterial Bloodstream Infections in Cameroon: A Systematic Review and Meta-Analysis of
2	Prevalence, and Antibiotic Resistance.
3	Moise Matakone1*‡, Patrice Landry Koudoum2‡, Ravalona Jessica Zemtsa3, Sen Claudine Henriette
4	Ngomtcho <sup>2,4</sup> , Isaac Dah <sup>1,5</sup> and Michel Noubom <sup>2,7</sup>
5	<sup>1</sup> National Veterinary Laboratory (LANAVET), Yaoundé, Cameroon;
6	<sup>2</sup> Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang P.O. Box 96,
7	Cameroon;
8	<sup>3</sup> Department of Biochemistry, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I,
9	Yaoundé, Cameroon;
10	<sup>4</sup> National Public Health Laboratory, Yaoundé, Cameroon;
11	<sup>5</sup> School of Veterinary Medicine and Science, University of Ngaoundéré, Ngaoundéré, Cameroon;
12	<sup>6</sup> Annex Regional Hospital of Dschang (ARHD), Dschang, Cameroon
13	*Corresponding author: moisematakone19@gmail.com;
14	‡ These authors contributed equally.
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	

## 33 Abstract

**Background:** The paucity of data on the epidemiology of bloodstream infection (BSI) in Low-and middle-income countries (LMICs) countries hampers its effective prevention and management. This review sought to provide the current prevalence, bacteriological and antimicrobial resistance profiles of bacteria implicated in BSI in Cameroon.

38 Methods: PubMed and Google Scholar databases were searched to identify relevant articles and 39 screened according to the PRISMA guidelines. Data was analysed using comprehensive meta-analysis 40 software. The l<sup>2</sup> was used to evaluate heterogeneity between studies, funnel plot and Egger's test to 41 evaluate publication bias and random-effects analysis models to calculate pooled prevalence.

42 Results: The 10 eligible studies were carried out in only two of the 10 regions of Cameroon and 43 investigated 4,223 participants, of whom 920 were children under two years old. The overall pooled 44 prevalence of bacterial BSI was 26.36% (95%CI= 17.51%-37.64%). Klebsiella spp. (28.20%; 95%CI= 45 2.80%-63.60%), Escherichia coli (18.94%; 95%CI= 13.02%-26.72%) and Staphylococcus aureus 46 (14.40%; 95%CI= 8.31%-23.81%) were the most incriminated bacteria species. E. coli and Klebsiella 47 spp. displayed the highest resistance to amoxicillin (82.6%; 95%CI= 63.3%-92.9 vs 86.4%; 95%CI= 48 55.9%-97.0%), amoxicillin + clavulanic acid (71.7%; 95%Cl= 0.44%-89.2% vs 73.1%; 95%Cl= 49 38.7%-92.1%) and trimethoprim/sulfamethoxazole (76.2%; 95%CI= 51.3%-90.7% vs 69.5%; 95%CI= 52.3-82.6%) respectively. However, meropenem (26.7%; 95%CI= 20.8%-33.7%) and fosfomycin 50 51 (14.9%; 95%CI= 9.1%-23.4%) were the least resistant in E. coli and Klebsiella spp. respectively. 52 Staphylococcus aureus showed high resistance to penicillin (84.4%; 95%CI= 68.1%-93.2%), 53 erythromycin (41.5%; 95%CI= 28.0%-56.5%) and oxacillin (37.4%; 95%CI= 8.8%-78.7%) and low 54 resistance to rifampicin (2.9%; 95%Cl= 0.6%-13.4%), fusidic acid (8.1%; 95%Cl= 3.4%-18.0%) and 55 vancomycin (13.6%; 95%Cl= 2.2%-52.9%).

56 **Conclusion:** This study reports a high prevalence of bacterial BSIs in Cameroon and the high 57 resistance of these bacteria to common antibiotics. There is a pressing need to conduct BSI surveillance 58 studies in all regions of Cameroon to generate data for evidence-based measures regarding BSI 59 prevention and management.

60 **Keywords:** Bloodstream infection, epidemiology, *Enterobacterales,* antibiotic resistance, Cameroon.

- 61
- 62
- 63 64
- 65

66

00

67

### 68 Introduction

69 Bloodstream infection (BSI) is characterised by positive blood cultures in patients with systemic 70 symptoms and signs of infection [1]. BSI can eventually lead to sepsis which is a complication 71 characterised by a life-threatening organ dysfunction caused by a dysregulated host response to 72 infection [1]. Sepsis and BSI are significantly associated with morbidity and mortality worldwide and 73 represent a huge public health concern [2]. According to the World Health Organization (WHO), sepsis 74 accounted for around 20% of all global deaths in 2017, affected 49 million people, and resulted in 11 75 million fatalities [2, 3]. Vulnerable populations such as pregnant women, elderly persons, patients with 76 severe comorbidities, newborns, and those in low-resource settings are disproportionately affected [4, 77 5]. Cases of sepsis and sepsis-related deaths in low-and middle-income countries (LMICs) account for 78 85% of the global sepsis incidence [3] and hospital mortality due to sepsis is estimated at 19% for 79 moderate sepsis and 39% for severe sepsis in sub-Saharan Africa (SSA) [6]. Bacteria, especially 80 Enterobacterales including Escherichia coli, Klebsiella spp., Salmonella enterica and Gram-positive 81 cocci such as Staphylococcus aureus and coagulase-negative Staphylococcus are all major species 82 implicated in BSI and sepsis [7, 8]. 83 Inappropriate use of antibiotics is known to exacerbate the burden of Antimicrobial Resistance (AMR) 84 in bacterial pathogens [9]. Globally, there is an increase in drug resistance to front-line antibiotics 85 including  $\beta$ -lactams, fluoroquinolones, aminoglycosides, and macrolides [10, 11]. Therefore, AMR is a

- 86 major public health concern and is expected to be the leading cause of mortality by 2050 with 10 million
- deaths per year if no immediate measures are taken [12]. AMR is a serious challenge in hospital settings
  as it worsens the effects of bacterial infections in general especially sepsis, from extended hospital
- 89 stays to increased mortality [13, 14].

In Cameroon, the bacterial BSI and sepsis and the AMR rate of implicated bacteria are still poorly documented. Notwithstanding, some studies have been published, it would be important to summarise these already available data to inform on context-specific epidemiology of BSI in terms of aetiology, AMR rate and to direct future BSI and sepsis prevention and management efforts in Cameroon. Thus, in this review, we estimate the pooled proportion of culture-confirmed bacterial BSIs and their AMR rates in Cameroon.

### 96 Methods

We conducted this systematic review and meta-analysis following the Preferred Reporting Items for
Systematic Review and Meta-Analysis statement (PRISMA) 2020 guidelines [15] and, the protocol was
registered in the Prospero database (Ref: CRD42023482760, available
from: <u>https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42023482760</u>).

## 101 Search strategy

102 The National Library of Medicine database (MEDLINE) was searched through PubMed, along with 103 Google Scholar and hand search. These databases were searched to find all articles reporting the 104 prevalence of culture-confirmed bacteria-driven bloodstream infections. Library research was performed using Medical Subject Headings (MeSH) and keywords paired with Boolean operators (Fig.106 1).

## 107 Eligibility criteria

108 Three authors independently searched the literature and evaluated the titles and abstracts of papers. 109 Articles included were studies which (1) reported culture-confirmed bacteria-driven bloodstream 110 infections in Cameroon, (2) published in peer-reviewed journals and (3) published in English or French 111 from 2010 up to December 2023. Articles were excluded if (1) the full texts were not assessable and 112 (2) they were case reports or case series.

#### 113 Study selection

- After the literature search, we uploaded all articles to an EndNote (version 20.6) database and duplicates were removed. Two reviewers did the screening of titles and abstracts to assess whether specific inclusion criteria were met and non-relevant citations and those that did not meet inclusion
- 117 criteria were excluded. Disagreements on whether or not an article should be included or not were
- 118 resolved by a third reviewer.

### 119 Data extraction

Two authors used a Microsoft Excel spreadsheet (2016 version) to extract data from included articles independently. The first author, publication year, region of study, study design, sample size, age of study population, the prevalence of BSIs, the proportion of each bacteria causing BSIs and AMR rates of bacteria groups were extracted. Inconsistencies were resolved through a group consensus.

### 124 Quality assessment

Quality of included studies was done using the Joanna Briggs Institute revised Critical Appraisal Checklist [16]. The checklist was applied to each study to assess the eight items with each item awarded a point for "yes" and the final score for each article added and fell between zero and eight. Any disagreement among authors was resolved by consensus. A study was considered low-risk when it scored  $\geq$  4 points.

## 130 Data analysis

We exported the extracted data to Comprehensive Meta-Analysis Software (version 3.0) for analysis. Begg and Egger's regression tests were used to objectively assess publication bias while the funnel plot was used to visualise this bias [17]. A *p*-value < 0.05 was considered statistically significant [18]. Cochrane Q statistics assessed the presence and magnitude of heterogeneity between studies. Quantification of heterogeneity was done using l<sup>2</sup> expressed in percentages. Values of 75, 50 and 25% were considered as high, medium and low heterogeneity [19] respectively. Subgroup meta-analysis was conducted according to participant's ages into all ages and paediatric (children under 2 years).

138

139

### 140 Results

## 141 **Results of the literature search**

- 142 The online database search from PubMed and Google Scholar yielded 329 articles and two articles
- through the hand search. The duplicates were removed and 314 articles were enrolled for the title and
- abstract screening. Finally, 25 articles were screened for full-text review and 10 which responded to the
- study objectives were included (**Fig. 2**).

#### 146 **Publication bias**

- 147 When BSI among study participants was analysed, a visual inspection of the funnel plot showed that
- there was no evidence of publication bias among the included studies. Similarly, the coefficient (4.89,
- 149 95% Cl= -5.23, 15.01) for Egger's regression test was not statistically significant (*p-value* = 0.298).

# 150 Characteristics of included studies

- 151 The 10 included studies described a total of 4223 blood cultures, of which 920 (21.79%) were performed
- 152 exclusively in the paediatric population (children under 2 years). The studies were conducted in two of
- the 10 regions of Cameroon and included patients from only two cities Douala (n=2547; 60.31%) [20-
- 154 22] and Yaoundé (n=1676; 39.69%) [23-29]. Most of the studies were cross-sectional (n=08) [20, 22-
- 155 26, 28, 29], one longitudinal [27] and one retrospective [21] study but all were of low-risk quality. Only
- the cross-sectional studies reported the age of the patients which ranged from 0 to 92 years (**Table 1**).

## 157 **Pooled prevalence and bacterial aetiology of bloodstream infections**

- The heterogeneity among the included studies was statistically significant (I<sup>2</sup>= 97,63%; p=0.000). Thus, we used Random Effect Models to calculate the pooled prevalence of culture-confirmed bacteria-driven bloodstream infections in Cameroon and their 95% confidence intervals were represented on forest plots. Blood culture was performed in 4223 patients and 888 were positive for a bacterial BSI. The bacterial BSI prevalence in this study ranged from 11.93% up to 67.89% and the overall pooled prevalence was 26.36% (95%CI= 17.51%–37.64%). Additionally, the prevalence in children and all age subgroups was similar (26.54% and 26.22% respectively) (**Fig. 3**).
- 165 The main bacterial groups reported in this study were Enterobacterales, Staphylococci and
- Streptococci. Among the Enterobacterales group, Klebsiella spp. (28.20%; 95%Cl= 2.80%–63.60%)
  was the most implicated followed by Escherichia coli (18.94%; 95%Cl= 13.02%–26.72%), Enterobacter
- 168 spp. (7.66%; 95%Cl= 4.46%–12.83%) and *Salmonella enterica* (7.01%; 95%Cl= 3.62%–13.15%)
- 169 (**Fig.4**). Seven studies reported gram-positive cocci, of which *Staphylococcus aureus* was the most
- 170 implicated (14.40%; 95%CI= 8.31%-23.81%), followed by *Coagulase-negative Staphylococcus*
- 171 (8.23%; 95%Cl= 2.68%–22.65%) (**Fig. 5**) and *Streptococcus* spp. (4.07%; 95%Cl= 2.64%–6.21%) as
- presented in **Fig. 6**. Non-fermenting gram-negative bacilli were also recorded in both age groups and
- 173 Acinetobacter spp. (3.93%; 95%CI=2.13%-7.29%) was the commonly reported followed by
- 174 *Pseudomonas* spp. (3.17%; 95%Cl= 1.96%–5.07%) (**Fig. 7**).

#### 176 Antimicrobial resistance rates of bacterial BSI

177 This study reported only the pooled AMR rate of the most represented bacteria in each group. Most of 178 the included studies failed to report the AST of several antibiotics. Overall, both E. coli and Klebsiella spp. were highly resistant to amoxicillin 82.6% (95%CI= 63.3%-92.9%) vs 86.4% (95%CI= 179 55.9%-97.0%), amoxicillin + clavulanic acid 71.7% (95%Cl= 0.44%-89.2%) vs 73.1% (95%Cl= 180 38.7%-92.1%) and trimethoprim/sulfamethoxazole 76.2% (95%CI= 51.3%-90.7%) vs 69.5% (95%CI= 181 182 52.3%-82.6%) respectively. Additionally, resistance to third and fourth-generation cephalosporins and 183 monobactam was high among E. coli: cefotaxime 46.5% (95%Cl= 26.8%-67.3%), ceftazidime 49.9% 184 (95%Cl= 29.5%-70.3%), cefepime 51.5% (95%Cl= 10.9%-62.0%), aztreonam 49.9% (95%Cl= 40.6%-185 59.3%) and Klebsiella spp.: cefotaxime 30.4% (95%CI= 9.8%-63.6%), ceftazidime 45.4% (95%CI= 186 16.8%-77.1%) and aztreonam 54.2% (95%CI= 34.2%-73.0%). However, meropenem 26.7% (95%CI= 20.8-33.7%) and fosfomycin 14.9% (95%Cl= 9.1%-23.4%) were the most effective in E. coli and 187 188 Klebsiella spp. respectively (Table 2). Staphylococcus aureus showed high resistance to penicillin 84.4% (95%CI= 68.1%-93.2%), erythromycin 41.5% (95%CI= 28.0%-56.5%) and oxacillin 37.4% 189 190 (95%CI= 8.8%-78.7%). However, a low resistance rate of Staphylococcus aureus was recorded in 191 non-β-lactams antibiotics including rifampicin 2.9% (95%CI= 0.6%-13.4%), fusidic acid 8.1% (95%CI= 3.4%-18.0%) and vancomycin 13.6% (95%CI= 2.2%-52.9%) and cefoxitin 18.9% (95%CI= 192 12.0%–82.1%) was the most effective  $\beta$ -lactams. In the CONS group, a high resistance rate was 193 194 registered against penicillin 89.9% (95%CI= 66.0%-97.6%), trimethoprim/sulfamethoxazole 52.9% (95%CI= 42.1%-63.5%) and oxacillin 50.7% (95%CI= 25.0%-76.1%) while cefoxitin 14.9% (95%CI= 195 196 11%-73.6%) and fusidic acid 25.5% (95%Cl= 17.4%-35.6%) were the most effective (Table 3).

### 197 Discussion

This review aimed to determine the pooled prevalence of bacterial BSIs and the AMR rates of implicated 198 199 bacteria in Cameroon. The 10 studies selected for this review described 4223 blood cultures and the 200 overall pooled prevalence of BSI in was 26.36%. This prevalence is higher than those reported in Africa 201 by Reddy et al (2010) and in Africa and Asia by Marchello et al (2019) which were 7.4% and 10.8% 202 respectively [30, 31]. However, studies conducted in Ethiopia by Bitew et al (2023), Legese et al (2022) 203 and Abebe et al (2021) documented a similar prevalence of BSI [32-34]. This review also recorded a 204 high prevalence of 26.54% of BSI in children under 2 years old. A similar pooled prevalence of neonatal 205 sepsis in East Africa was documented by Abate et al (2020) [35] while Belachew and Tewabe (2020) 206 recorded a pooled prevalence of neonatal sepsis in Ethiopia of 49.98% [36]. The observed difference 207 and the high prevalence either in children and all age groups in this review may be due to the small 208 sample size of many included studies [20, 22, 27, 28], the study design as well as the study periods.

The study revealed that *Enterobacterales* including *Klebsiella* spp. (28.20%) and *Escherichia coli* (18.94%) were the leading bacteria implicated in the BSI. Studies conducted in several low and middleincome countries have demonstrated the high implication of these bacteria in bloodstream infections and sepsis especially in hospital settings [10, 34, 37]. However, these results were contradictory to those recorded by Wattal *et al* (2020) and Reddy *et al* (2010) where *Salmonella* spp. was the leading

- cause of BSI and sepsis [11, 30]. This contradiction might be due to the bacterial identification methods
- used poorly described in some studies which can considerably vary depending on the laboratory [20,
- 216 21, 27].
- 217 The most frequent *Enterobacterales* reported in this review showed a high resistance to  $\beta$ -lactam
- 218 antibiotics especially third and fourth-generation cephalosporins and monobactam. This might indicate
- 219 the production of  $\beta$ -lactamases particularly the extended-spectrum  $\beta$ -lactamase enzymes by most of
- these bacteria even though most of the included studies failed to report the resistance phenotypes.

# 221 Limitations

- The statements and conclusions in this review cannot be generalised to Cameroon as the included studies investigated only two regions and were conducted in a small sample size. Also, the study was unable to precise whether the BSI was community or hospital-acquired. Finally, the study failed to report
- 225 AMR among several bacteria and the resistance phenotypes of implicated bacteria.

# 226 Conclusion

227 The prevalence of bacterial bloodstream infection in this study is elevated in both paediatric and adult 228 populations. Enterobacterales including Klebsiella spp. and Escherichia coli and Gram-positive cocci 229 particularly Staphylococcus aureus remain the leading causes of bloodstream infection. Antibiotic 230 resistance was higher to β-lactam in both *Enterobacterales* and Gram-positive cocci. This study may 231 help clinicians optimise their antibiotic prescription protocol in the early management of bacterial 232 bloodstream infection in the absence of antibiotic susceptibility testing results. The review also calls for 233 researchers to make more effort to produce AMR data to permit policymakers and stakeholders a better 234 bloodstream infection management and prevention in Cameroon.

## 235 Conflict of interest

236 The authors declare no conflict of interest

## 237 Authors contributions

- 238 MM conceived and designed the study. MM and PLK coordinated the literature search. PKL, RJZ and
- 239 MM undertook data extraction, quality assessment and statistical analysis. MM, PLK, and RJZ prepared
- 240 the first draft of the manuscript. ID, SCHN and MN critically reviewed the manuscript. All authors read
- and approved the final version of the manuscript.

## 242 Funding

243 The study was not funded.

# 244 References

[1]. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, *et al.* The
Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama.
2016;315(8):801-10.

- 248 [2]. WHO. Global report on the epidemiology and burden of sepsis: Current evidence, identifying249 gaps and future directions. 2020.
- [3]. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, *et al.* Global, regional,
  and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease
  Study. Lancet. 2020;395(10219):200-11.
- [4]. Cheng AC, West TE, Limmathurotsakul D, Peacock SJ. Strategies to reduce mortality from
  bacterial sepsis in adults in developing countries. PLoS Med. 2008;5(8):e175.
- [5]. Rhee C, Jones TM, Hamad Y, Pande A, Varon J, O'Brien C, *et al.* Prevalence, Underlying
  Causes, and Preventability of Sepsis-Associated Mortality in US Acute Care Hospitals. JAMA Netw
  Open. 2019;2(2):e187571.
- [6]. Lewis JM, Feasey NA, Rylance J. Aetiology and outcomes of sepsis in adults in sub-Saharan
  Africa: a systematic review and meta-analysis. Critical Care. 2019;23(1):212.
- [7]. Timsit JF, Ruppé E, Barbier F, Tabah A, Bassetti M. Bloodstream infections in critically ill
  patients: an expert statement. Intensive Care Med. 2020;46(2):266-84.
- [8]. Mun SJ, Kim S-H, Kim H-T, Moon C, Wi YM. The epidemiology of bloodstream infection
  contributing to mortality: the difference between community-acquired, healthcare-associated, and
  hospital-acquired infections. BMC Infectious Diseases. 2022;22(1).
- [9]. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic
  resistance. Nat Rev Microbiol. 2015;13(1):42-51.
- 267 [10]. Ombelet S, Kpossou G, Kotchare C, Agbobli E, Sogbo F, Massou F, *et al.* Blood culture
  268 surveillance in a secondary care hospital in Benin: epidemiology of bloodstream infection pathogens
  269 and antimicrobial resistance. BMC Infect Dis. 2022;22(1):119.
- [11]. Wattal C, Goel N. Pediatric Blood Cultures and Antibiotic Resistance: An Overview. Indian J
  Pediatr. 2020;87(2):125-31.
- 272 [12]. O'Neill J. Tackling drug-resistance infections globally: final report and recommendations, 2016.
- Available: <u>https://amr-review.org/sites/default/files/160518\_Final%20paper\_with%20cover.pdf</u>
  [Accessed on 1 Jul 2023] 2016 [
- [13]. Chaurasia S, Sivanandan S, Agarwal R, Ellis S, Sharland M, Sankar MJ. Neonatal sepsis in
  South Asia: huge burden and spiralling antimicrobial resistance. Bmj. 2019;364:k5314.
- 277 [14]. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, *et al.* Global
  278 burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet.
  279 2022;399(10325):629-55.
- [15]. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, *et al.* The PRISMA
  2020 statement: An updated guideline for reporting systematic reviews. PLoS Med.
  2021;18(3):e1003583.
- [16]. Joanna Briggs Institute. Critical-Appraisal-Tools—Critical Appraisal Tools I JBI. 2022. Available
  online: <a href="https://jbi.global/critical-appraisal-tools">https://jbi.global/critical-appraisal-tools</a> (accessed on 07 November 2023).
- [17]. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple,
  graphical test. Bmj. 1997;315(7109):629-34.

[18]. Fletcher J. What is heterogeneity and is it important? Bmj. 2007;334(7584):94-6.

[19]. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses.
Bmj. 2003;327(7414):557-60.

[20]. Kemeze S, Moudze B, Chiabi A, Eposse C, Kaya A, Mbangue M, *et al.* Profil clinique et
bactériologique des infections néonatales bactériennes à l'Hôpital Laquintinie de Douala, Cameroun.

292 The Pan African Medical Journal. 2016;23.

[21]. Okalla Ebongue C, Mefo'o JP, Te N, Moukoko E, Adiogo D, Beyiha G. Profil Bactériologique et
sensibilité aux antibiotiques des isolats d'hémoculture (2006 – 2011) à Douala, Cameroun. Revue
Malienne d'Infectiologie et de Microbiologie. 2014;2.

296 [22]. Teghonong J, Okalla Ebongue C, Yadufashije C, Kojom LP, Adiogo D. Phenotypic
 297 Characteristics of Klebsiella pneumoniae Extended Spectrum β-Lactamases Producers Isolated in
 298 Hospitals in the Littoral Region, Cameroon. European Journal of Clinical Microbiology. 2020;6:9-13.

[23]. Carole Suzie Lacmago Titsamp HKG, Simon Ngamli Fewou. Bloodstream infections initiated
by ESBL-producing Escherichia coli in neonates and infants at two hospitals in Yaoundé, Cameroon.
International Journal of Biological and Chemical Sciences. 2021;15(3).

302 [24]. Chiabi A, Djoupomb M, Mah E, Nguefack S, Mbuagbaw L, Zafack J, *et al.* The clinical and
303 bacteriogical spectrum of neonatal sepsis in a tertiary hospital in yaounde, cameroon. Iran J Pediatr.
304 2011;21(4):441-8.

305 [25]. Djuikoue CI, Djouela Djoulako PD, Wouambo RK, Lacmago ST, Dayomo A, Kamga HG, *et al.*306 Prevalence of Escherichia coli Producing Extended Spectrum Beta-Lactamase (ESBL) Driven
307 Septicaemia in Children Aged 0–2 Years in Two Districts Hospitals in Yaounde, Cameroon. Bacteria.
308 2022;1(4):294-301.

309 [26]. Kamga H, Njunda A, Nde P, Assob J, Nsagha D, Weledji P. Prevalence of septicaemia and
310 antibiotic sensitivity pattern of bacterial isolates at the University Teaching Hospital, Yaoundé,
311 Cameroon. African Journal of Clinical and Experimental Microbiology. 2011;12(1).

[27]. Nouetchognou JS, Ateudjieu J, Jemea B, Mesumbe EN, Mbanya D. Surveillance of nosocomial
 infections in the Yaounde University Teaching Hospital, Cameroon. BMC Res Notes. 2016;9(1):505.

Yimtchi LCN, Pokam BDT, Baiye AW, Betbeui AC, Gonsu HK, Djakissam W. Antibiotic
 Susceptibility Patterns of Bacteria Associated with Sepsis among Hospitalized Patients in the Yaoundé
 University Teaching Hospital—Cameroon. Open Journal of Medical Microbiology. 2023;13(1):101-15.

317 [29]. Zefack JT, Ambe NF, Bobga TP, Ketum AS, Awambeng DN, Kelly CN, *et al.* Bacteriological
318 Profile and Antimicrobial Sensitivity Pattern of Blood Culture Isolates among Septicemia Suspected

Patients in the University Teaching Hospital (UTH) Yaoundé, Cameroon. International Journal of Trend
in Scientific Research and Development.2020;4(5).

321 [30]. Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a
322 systematic review and meta-analysis. The Lancet infectious diseases. 2010;10(6):417-32.

[31]. Marchello CS, Dale AP, Pisharody S, Rubach MP, Crump JA. A Systematic Review and Meta analysis of the Prevalence of Community-Onset Bloodstream Infections among Hospitalized Patients
 in Africa and Asia. Antimicrob Agents Chemother. 2019;64(1).

- 326 [32]. Bitew A, Adane A, Abdeta A. Bacteriological spectrum, extended-spectrum β-lactamase
  327 production and antimicrobial resistance pattern among patients with bloodstream infection in Addis
  328 Ababa. Scientific Reports. 2023;13(1).
- [33]. Abebe W, Tegene B, Feleke T, Sharew B. Bacterial Bloodstream Infections and their
  Antimicrobial Susceptibility Patterns in Children and Adults in Ethiopia: a 6-Year Retrospective Study.
  Clin Lab. 2021;67(11).
- [34]. Legese MH, Asrat D, Swedberg G, Hasan B, Mekasha A, Getahun T, *et al.* Sepsis: emerging
  pathogens and antimicrobial resistance in Ethiopian referral hospitals. Antimicrobial Resistance &
  Infection Control. 2022;11(1):83.
- 335 [35]. Abate BB, Kasie AM, Reta MA, Kassaw MW. Neonatal sepsis and its associated factors in East
  336 Africa: a systematic review and meta-analysis. International Journal of Public Health. 2020;65(9):1623337 33.
- 338 [36]. Belachew A, Tewabe T. Neonatal sepsis and its association with birth weight and gestational
  339 age among admitted neonates in Ethiopia: systematic review and meta-analysis. BMC Pediatrics.
  340 2020;20(1).
- 341 [37]. Solomon S, Akeju O, Odumade OA, Ambachew R, Gebreyohannes Z, Van Wickle K, et al.
- 342 Prevalence and risk factors for antimicrobial resistance among newborns with gram-negative sepsis.
- 343 PLOS ONE. 2021;16(8):e0255410.



Fig. 1: Search terms used to identify relevant literature from PubMed and Google Scholar



Fig. 2: PRISMA flow chart of the study selection process



Fig. 3: Forest plot of pooled prevalence of culture-confirmed bacterial bloodstream infections in Cameroon



Fig. 4: Forest plot of pooled prevalence of Enterobacterales-driven BSI in Cameroon.

A: Klebsiella spp. ; B: Escherichia coli; C: Enterobacter spp. and D: Salmonella enterica





Fig. 5: Forest plot of pooled prevalence of Staphylococci-driven BSI in Cameroon.

E: Staphylococcus aureus and F: Coagulase negative Staphylococci

353

	Study		Pooled prevalence (%)	95%	CI (%)	Weight (%)
55	All age					
56	Ebongue et al, 2014		3,34	1,81	6,10	17,43
50	Kamga et al, 2011	D-	5,45	2,47	<b>11</b> ,61	17,23
57	Nouetchognou et al, 2016		3,85	0,24	40,32	15,33
,	Zefack et al, 2020	o	3,08	0,77	11,48	17,04
58	Yimtchi et al, 2023		2,00	0,12	25,13	<b>1</b> 6, <b>4</b> 1
	Subtotal (I <sup>2</sup> = 0.00%, p = 0.863)	\$	3,83	2,45	5,92	
59	Children (≤ 2 years ) only					
	Chiabi et al, 2011		19,23	8,24	38,70	24,64
50	Kemeze et al, 2016	þ——	2,78	0,17	32,21	23,67
	Subtotal (I <sup>2</sup> = 48.73%, p = 0.163)	>	11,22	1,85	45,85	
51	Overall (l <sup>2</sup> = 50.33%, p = 0.060)	+	4.07	2,64	6,21	
~~		0.0 40.0 8	30.0			
52	Note: Weights are from rando	m effect analys	sis			
63						

364 Fig. 6: Forest plot of pooled prevalence of *Streptococcus* spp. driven bloodstream infections in Cameroon

Bacteria species	Study	Pooled prevalence (%)	Pooled prevalence 95% (%)		Weight (%)	
	All age					
Acinetobacter spp.	Ebongue et al, 2014 Kamga et al, 2011 Nouetchognou et al, 2016 Zefack et al, 2020 Yimtchi et al, 2023 Subtotal ( $l^2 = 49.9\%$ , p = 0.264) <b>Children (<math>\leq 2 \ years</math> ) only</b> Chiabi et al, 2011		1,67 1,82 3,85 6,15 8,33 3,41 7,69	0,70 0,46 0,24 2,33 2,09 1,65	3,95 6,98 40,32 15,28 27,88 6,89 26,07	30,65 18,53 6,11 27,01 17,70 79,16
	Kemeze et al, 2016 Subtotal (l <sup>2</sup> = 0.00%, p = 0.507) <b>Overall (l<sup>2</sup> = 23.80%, p = 0.247)</b> Test of group differences: p = 0.400	•	2,78 6,25 <b>3,97</b>	0,17 1,81 <b>2,13</b>	32,21 19,39 <b>7,29</b>	20,84
	All age					
Pseudomonas spp.	Ebongue et al, 2014 Kamga et al, 2011 Nouetchognou et al, 2016 Zefack et al, 2020 Yimtchi et al, 2023 Subtotal (1 <sup>2</sup> = 49.9%, p = 0.264) <b>Children (5 2 years ) only</b>	□	3,68 2,73 3,85 0,76 2,00 3,24	2,05 0,88 0,24 0,05 0,12 1,98	6,52 8,11 40,32 10,98 25,13 5,26	70,73 19,48 3,21 3,31 3,27
	Chiabi et al, 2011 Kemeze et al, 2016 Subtotal (l <sup>2</sup> = 0.00%, p = 0.507) <b>Overall (l<sup>2</sup> = 23.80%, p = 0.247)</b> Test of group differences: p = 0.400		1,85 2,78 2,27 <b>3,17</b>	0,11 0,17 0,32 <b>1,96</b>	23,64 32,21 14,42 <b>5,07</b>	50,24 49,76

**Fig. 7:** Forest plot of pooled prevalence of non-fermenting Gram-negative bacteria-driven bloodstream infections

366 in Cameroon

Table 1: Summary characteristics of studies included in the meta-analysis	
Table 1. Summary charactensites of studies included in the meta-analysis	

Study period	Study type	City	Population	Age range	Positive	Quality	Authors
			size		cultures (%)		Study period
January-April 2018	Cross-sectional	Yaoundé	255	0-82 years	65 (25.50)	Low-risk	Zefack et <i>al</i> , 2020
August-October	Cross-sectional	Yaoundé	298	0-48 weeks	129 (43.30)	Low-risk	Titsamp et al,
2017							2021
August 2019-March	Cross-sectional	Yaoundé	300	0-2 years	130 (43.33)	Low-risk	Djuikoue <i>et al</i> ,
2020							2022
March-June 2015	Cross-sectional	Douala	104	0-28 days	17 (16.34)	Low-risk	Kemeze et al,
							2016
September 2013 -	Longitudinal	Yaoundé	59	NA	12 (20.34)	Low-risk	Nouetchognou et
March 2014							<i>al</i> , 2016
2006-2011	Retrospective	Douala	2334	NA	299 (12.81)	Low-risk	Ebongue et <i>al</i> ,
							2014
January-June 2010	Cross-sectional	Yaoundé	396	0->76 years	112 (28.30)	Low-risk	Kamga et <i>al</i> , 2011
November 2008-	Cross-sectional	Yaoundé	218	0-28 days	26 (11.92)	Low-risk	Chiabi <i>et al</i> , 2011
May 2009							
November 2021-	Cross-sectional	Yaoundé	150	10-92 years	24 (16)	Low-risk	Yimtchi et al, 2023
March 2022							
January 2016-	Cross-sectional	Douala	109	>1-71 years	74 (67.89)	Low-risk	Teghonong et al,
February 2017							2020

**Table 2:** Pooled prevalence of antibiotic resistance of *E. coli* and *Klebsiella* spp. isolated from bloodstream infections in Cameroon

Bacteria	Antibiotics	Number of studies	Number of isolates	Pooled prevalence of AMR (95% Cl)
	Amoxicillin	5	275	82.6 (63.3-92.9)
	Amoxicillin + Clavulanic acid	5	276	71.7 (0.44-89.2)
	Cefotaxime	3	263	46.5 (26.8-67.3)
<i>E. coli</i> N = 281	Ceftazidime	5	274	49.9 (29.5-70.3)
	Cefepime	3	187	51.5 (10.9-62.0)
	Cefoxitin	6	281	33.2 (18.5-52.0)
	Aztreonam	4	108	49.9 (40.6-59.3)
	Meropenem	3	180	26.7 (20.8-33.7)
	Amikacin	5	274	37.5 (18.7-61.1)
	Gentamicin	6	281	49.5 (37.3-61.7)
	Ciprofloxacin	5	191	41.7 (32.6-51.4)
	Nalidixic acid	3	185	34.6 (28.1-41.7)
	Trimethoprim/Sulfamethoxazole	5	275	76.2 (51.3-90.7)
	Amoxicillin	4	107	86.4 (55.9-97.0)
Klabajalla ana	Amoxicillin + Clavulanic acid	4	99	73.1 (38.7-92.1)
N = 115	Cefotaxime	3	99	30.4 (9.8-63.6)
	Ceftazidime	3	99	45.4 (16.8-77.1)
	Cefoxitin	4	107	35.8 (19.5-56.3)
	Aztreonam	3	24	54.2 (34.2-73.0)
	Fosfomycin	3	99	14.9 (9.1-23.4)
	Amikacin	4	107	26.8 (6.1-67.2)
	Gentamicin	5	115	44.8 (35.6-54.3)
	Ciprofloxacin	5	115	56.5 (29.9-79.8)
	Trimethoprim/Sulfamethoxazole	4	107	69.5 (52.3-82.6)

**Table 3:** Pooled prevalence of antibiotic resistance of *S. aureus* and Coagulase Negative *Staphylococcus*(CONS) isolated from bloodstream infections in Cameroon

Bacteria	Antibiotics	Number of	Total number of	Pooled prevalence of
		studies	isolates	AMR (95% CI)
	Penicillin	2	61	84.4 (68.1-93.2)
	Oxacillin	3	62	37.4 (8.8-78.7)
	Cefoxitin	3	29	18.9 (12.0-82.1)
	Gentamicin	4	68	30.2 (20.3-42.3)
	Erythromycin	4	68	41.5 (28.0-56.5)
S. aureus	Lincosamin	2	62	27.4 (3.6-79.1)
N = 68	Tetracycline	4	68	29.3 (5.6-74.2)
	Rifampicin	3	61	2.9 (0.6-13.4)
	Trimethoprim/Sulfamethoxazole	3	62	29.8 (19.6-42.5)
	Fusidic acid	3	62	8.1 (3.4-18.0)
	Vancomycin	3	68	13.6 (2.2-52.9)
	Penicillin	3	93	89.9 (66.0-97.6)
	Oxacillin	3	93	50.7 (25.0-76.1)
	Cefoxitin	2	71	14.9 (11-73.6)
CONS	Gentamicin	3	93	36.7 (18.7-59.4)
N = 93	Erythromycin	3	93	46.8 (27.3-67.4)
	Lincosamin	3	93	42.0 (32.2-52.5)
	Tetracycline	3	93	41.7 (27.0-58.1)
	Trimethoprim/Sulfamethoxazole	3	93	52.9 (42.1-63.5)
	Fusidic acid	3	93	25.5 (17.4-35.6)
	Vancomycin	3	93	30 (14.4-53.2)